Eileen Holmes

2.6k total citations
32 papers, 1.0k citations indexed

About

Eileen Holmes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eileen Holmes has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Eileen Holmes's work include HER2/EGFR in Cancer Research (16 papers), Breast Cancer Treatment Studies (9 papers) and Advanced Breast Cancer Therapies (5 papers). Eileen Holmes is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Breast Cancer Treatment Studies (9 papers) and Advanced Breast Cancer Therapies (5 papers). Eileen Holmes collaborates with scholars based in United Kingdom, United States and Belgium. Eileen Holmes's co-authors include Martine Piccart, Richard D. Gelber, Moe H. Kyaw, Harry Campbell, Ian Jones, Evandro de Azambuja, Jim Chalmers, José Baselga, Sherene Loi and Andrew Wardley and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Eileen Holmes

32 papers receiving 989 citations

Peers

Countries citing papers authored by Eileen Holmes

Since Specialization

Citations

This map shows the geographic impact of Eileen Holmes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eileen Holmes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eileen Holmes more than expected).

Fields of papers citing papers by Eileen Holmes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eileen Holmes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eileen Holmes. The network helps show where Eileen Holmes may publish in the future.

Co-authorship network of co-authors of Eileen Holmes

This figure shows the co-authorship network connecting the top 25 collaborators of Eileen Holmes. A scholar is included among the top collaborators of Eileen Holmes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eileen Holmes. Eileen Holmes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines 2023 ·International Journal of Technology Assessment in Health Care ·(unknown), Louise Taylor, (unknown), Eileen Holmes	1
2	811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 2020 ·Annals of Oncology ·Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro	47
3	234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 2020 ·Annals of Oncology ·Michael Friedländer, (unknown), Nicoletta Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, (unknown), Antonio González-Martı́n, (unknown), (unknown), Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro	1
4	A feasibility study of microwave therapy for precancerous actinic keratosis 2020 ·British Journal of Dermatology ·(unknown), Fiona Hogarth, (unknown), Eileen Holmes, Peter T. Donnan, Charlotte M. Proby	7
5	Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial 2019 ·Annals of Oncology ·Eileen Holmes, Ian Bradbury, (unknown), Larissa A. Korde, Evandro de Azambuja, Debora Fumagalli, Alvaro Moreno‐Aspitia, José Baselga, Martine Piccart, (unknown), Richard D. Gelber	4
6	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. 2017 ·Journal of Clinical Oncology ·Jens Huober, Eileen Holmes, José Baselga, Evandro de Azambuja, Michael Untch, Debora Fumagalli, Séverine Sarp, István Láng, Ian E. Smith, Frances Boyle, Binghe Xu, (unknown), Lorena de la Peña, Christian Jackisch, Richard D. Gelber, Martine Piccart, Serena Di Cosimo	6
7	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial 2016 ·JNCI Journal of the National Cancer Institute ·Isabelle Gingras, Eileen Holmes, Evandro de Azambuja, David H. Nguyen, Miguel Izquierdo, Jo Anne Zujewski, Moshe Inbar, Bjørn Naume, Gianluca Tomasello, Julie R. Gralow, Antonio C. Wolff, Lyndsay N. Harris, Michael Gnant, Alvaro Moreno‐Aspitia, Martine Piccart, Hatem A. Azim	19
8	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial 2016 ·Annals of Oncology ·Wenhao Shi, Tingting Jiang, Paolo Nucíforo, Christos Hatzis, Eileen Holmes, Nadia Harbeck, (unknown), (unknown), Sherene Loi, (unknown), Sin Eng Chia, Andrew Wardley, Takayuki Ueno, José Roberto Freitas Rossari, Holger Eidtmann, Alison Armour, (unknown), David L. Rimm, J. Baselga, Lajos Pusztai	51
9	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 2016 ·Annals of Oncology ·S. Loibl, Ian J. Majewski, Valentina Guarneri, Valentina Nekljudova, Eileen Holmes, Emilio Bria, Carsten Denkert, Christian Schem, Christos Sotiriou, Sherene Loi, Michael Untch, Pierfranco Conté, René Bernards, Martine Piccart, Gϋnter von Minckwitz, José Baselga	146
10	Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status 2015 ·Annals of Oncology ·Paolo Nucíforo, Claudia Aura, Eileen Holmes, Ludmila Prudkin, José Jiménez, Paula Felippe Martinez, (unknown), Lorena de la Peña, (unknown), Holger Eidtmann, Martine Piccart, Maurizio Scaltriti, José Baselga	27
11	Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies 2015 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Lajos Pusztai, (unknown), Tingting Jiang, Paolo Nucíforo, Eileen Holmes, Nadia Harbeck, Christos Sotiriou, (unknown), Christos Hatzis, Lorena de la Peña, Alison Armour, Martine Piccart, José Baselga	1
12	Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc) 2014 ·Annals of Oncology ·EA Perez, Eileen Holmes, Evandro de Azambuja, (unknown), José Baselga, (unknown), (unknown), Aron Goldhirsch, Rocco J. Crescenzo, K.I. Pritchard, Antonio C. Wolff, Christian Jackisch, (unknown), Michael Untch, I E Smith, (unknown), Bing Xu, Henry Gómez, R.D. Gelber, M. Piccart	2
13	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) 2013 ·The Lancet Oncology ·Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, (unknown), (unknown), István Láng, Andrew Wardley, Mikhail Lichinitser, (unknown), Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron	142
14	Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial 2013 ·Journal of Clinical Oncology ·Ann H. Partridge, Shari Gelber, Martine Piccart, (unknown), (unknown), Eileen Holmes, Eric P. Winer, Richard D. Gelber	86
15	Maturity and medical students’ ease of transition into the clinical environment 2009 ·Medical Teacher ·(unknown), Eileen Holmes, Graham Mason, Ioan Davies, Tim Dornan	46
16	The North West Diabetic Pregnancy Audit: a practical system for multi‐centre diabetic pregnancy audit 2008 ·Diabetic Medicine ·R. J. Young, Eileen Holmes, I. F. Casson, Michael Maresh	4
17	Evaluation of Severe Infection and Survival After Splenectomy 2006 ·The American Journal of Medicine ·Moe H. Kyaw, Eileen Holmes, (unknown), (unknown), Jim Chalmers, Ian Jones, Harry Campbell	111
18	PREDICTION OF INFECTIOUS DISEASES:AN EXCEPTION REPORTING SYSTEM 2003 ·Journal of Medical Informatics & Technologies ·(unknown), David G. Greenhalgh, G. Gettinby, Eileen Holmes, John Cowden	5
19	A survey of vaccine coverage and antibiotic prophylaxis in splenectomised patients in Scotland 2002 ·Journal of Clinical Pathology ·Moe H. Kyaw, Eileen Holmes, Jim Chalmers, Ian Jones, Harry Campbell	34
20	Influenza and pneumococcal vaccination in Scottish nursing homes: coverage, policies and reasons for receipt and non-receipt of vaccine 2002 ·Vaccine ·Moe H. Kyaw, (unknown), Eileen Holmes, Ian Jones, Harry Campbell	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact